

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

PEER-REVIEW REPORT

Name of journal: World Journal of Virology

Manuscript NO: 88660

Title: Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic

review and meta-analysis

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03259512 Position: Editorial Board Academic degree: MSc, PhD

Professional title: Assistant Professor, Senior Researcher

Reviewer's Country/Territory: Australia

Author's Country/Territory: Iran

Manuscript submission date: 2023-10-04

Reviewer chosen by: AI Technique

Reviewer accepted review: 2023-10-04 23:48

Reviewer performed review: 2023-10-05 00:37

Review time: 1 Hour

	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C:
Scientific quality	Good
	[] Grade D: Fair [] Grade E: Do not publish
Novelty of this manuscript	[Y] Grade A: Excellent [] Grade B: Good [] Grade C: Fair [] Grade D: No novelty
Creativity or innovation of	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair
this manuscript	[] Grade D: No creativity or innovation



Baishideng

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[] Grade A: Excellent [Y] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [] Accept (General priority) [] Minor revision [Y] Major revision [] Rejection
Re-review	[Y] Yes [] No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [] Onymous Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The current study is a meta-analysis that aims to assess treatment of COVID-19 with bamlanivimab. The study is interesting and may attract lots of attention. However, there are issues to address. 1. Abstract/methods. Keywords used for the search of literature should be indicated. The use of bamlanivimab alone should be indicated. 2. All abbreviations in the Abstract (and in the text - first time used) should be deciphered. ICU, ROB ... etc 3. Abstract/ tables: indicate the age group of assessed patients. 4. Tables; a median or mean age of patients should be indicated. Male% should be also indicated. If studies indicate dhte procentage of comorbidies/co-infections – it should be also discussed and indicated in a table. 5. Adverse events should be described in more details. 6. Authors did not mention the "long COVID" and associated long term debilitating symptoms. It is necessary to add this to the Discussion section (see this https://pubmed.ncbi.nlm.nih.gov/36100326/) 7. Indicate which SARS strains developed resistance to bamlanivimab. 8. Another missing point: co-infection with other Effect of different SARS-CoV-2 strains? (See Beeraka et al., 2022 agents? https://pubmed.ncbi.nlm.nih.gov/35416390/. It has be discussed. 9. to



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

Conclusions/future perspectives should indicate a direction for future assessments, including long COVID and assessment of the risk groups 9 aged population), co-infections, development of resistance etc.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Virology

Manuscript NO: 88660

Title: Efficacy and safety of bamlanivimab in patients with COVID-19: A systematic

review and meta-analysis

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03259512 Position: Editorial Board Academic degree: MSc, PhD

Professional title: Assistant Professor, Senior Researcher

Reviewer's Country/Territory: Australia

Author's Country/Territory: Iran

Manuscript submission date: 2023-10-04

Reviewer chosen by: Jing-Jie Wang

Reviewer accepted review: 2023-11-10 01:57

Reviewer performed review: 2023-11-13 02:41

Review time: 3 Days

Scientific quality	[] Grade A: Excellent [Y] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[] Grade A: Priority publishing [Y] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[] Accept (High priority) [Y] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568

https://www.wjgnet.com

E-mail: bpgoffice@wjgnet.com

statements

Conflicts-of-Interest: [] Yes [Y] No

SPECIFIC COMMENTS TO AUTHORS

The manuscript has been properly revised. Authors addressed all my comments. The text has been improved.